Lung Cancer: The addition of chemotherapy to EGFR inhibitor therapy improved survival in advanced EGFR-mutant NSCLC in two independent studies, compared with targeted therapy alone

por OncoDNA

4 years ago
Lung Cancer, chemotherapy, EGFR inhibitor therapy, Gefitinib

The addition of chemotherapy to EGFR inhibitor therapy improved survival in advanced EGFR-mutant NSCLC in two independent studies, compared with targeted therapy alone

Lung Cancer: Despite early encouraging results, the EGFR inhibitor poziotinib failed to meet its primary endpoint in the phase II ZENITH20 tria

por OncoDNA

4 years ago
Lung Cancer, EGFR, ZENITH20 trial, ORR, ZENITH20 trial’s Cohort

Despite early encouraging results, the EGFR inhibitor poziotinib failed to meet its primary endpoint in the phase II ZENITH20 trial. For patients with pre-treated NSCLC with EGFR exon 20 insertion mut...

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting

por Ability Pharma

5 years ago
ABTL0812, Endometrial, Lung Cancer, oncology drugs, clinical trial

AbilityPharma (Ability Pharmaceuticals, SL) a biopharmaceutical company developing oncology drugs, announced today that the company will release the first results of the currently ongoing phase 1/2a c...